ALGS Stock Summary and Trading Ideas (Aligos Therapeutics | NASDAQ:ALGS)

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Aligos Therapeutics trades on the NASDAQ stock market under the symbol ALGS.

As of October 14, 2026, ALGS stock price declined to $5.39 with 5,451 million shares trading.

ALGS has a beta of 1.49, meaning it tends to be more sensitive to market movements. ALGS has a correlation of 0.04 to the broad based SPY ETF.

ALGS has a market cap of $33.66 million. This is considered a Sub-Micro Cap stock.

Last quarter Aligos Therapeutics reported $0 in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-19 million and exceeded earnings estimates by $1.14.

In the last 3 years, ALGS traded as high as $46.80 and as low as $3.76.

The top ETF exchange traded funds that ALGS belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DFAS.

ALGS has underperformed the market in the last year with a price return of -43.1% while the SPY ETF gained +17.4%. ALGS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.3% and -4.1%, respectively, while the SPY returned +3.1% and +0.8%, respectively.

ALGS support price is $5.18 and resistance is $5.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALGS shares will trade within this expected range on the day.